Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2019 | Pages:
70 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global idiopathic pulmonary fibrosis (IPF) treatment market size is expected to reach a value of USD 5.2 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 12.7% during the forecast period. Increasing R&D initiatives undertaken by companies and surge in cigarette smoking population are anticipated to boost the growth. Rise in the initiatives undertaken by manufacturers to develop products with novel mechanisms is anticipated to fuel the IPF treatment market growth. For instance, FibroGen, Inc., is currently developing a drug, pamrevlumab - a monoclonal antibody that targets the connective tissue growth factor. The phase III trials of pamrevlumab are expected to be initiated in the first half of 2019. The drug has received fast track designation from the Food and Drug Administration (FDA). An aging population can be expected to have far-reaching social, economic, and political implications on nearly all the sectors including the healthcare sector. An associated consequence of an increase in the geriatric population will be an increase in the incidences of various medical conditions requiring long-term care. Moreover, the growing geriatric population base in countries with large untapped opportunities such as China and Japan is anticipated to drive the market growth during the forecast period. The dramatic increase in cigarette smoking population is one of the major drivers likely to have a positive impact on market growth. According to the U.S. FDA and Centers for Disease Control and Prevention (CDC), in 2018, more than 3.6 million high and middle school students were existing e-cigarette users. The number increased by 1.5 million since the last year. The uptake in the use of e-cigarette is expected to lead to the incidence of IPF. Further key findings from the study suggest: • MAPK Inhibitors segment held the largest market share in 2018. Esbriet is the first drug approved for the treatment of IPF • Tyrosine kinase inhibitor is the second largest segment and is expected to expand at a CAGR of 11.0% • Autotaxin inhibitors (GLPG1690) is expected to post lucrative CAGR. GLPG1690 is currently in phase III trial and is expected to be commercialized in 2022 • U.S. led in 2018 due to high market penetration and high awareness pertaining to IPF • IPF treatment market in Japan is estimated to decline over the forecast period owing to patent expiry of Esbriet in 2018 • Some of the major players operating in the Idiopathic Pulmonary Fibrosis treatment market are F. Hoffman La-Roche Ltd; Boehringer Ingelheim International GmbH; Galapagos; FibroGen, Inc.; Prometic Life Sciences Inc.; Bristol-Myers Squibb Company; MediciNova, Inc.; Merck & Co., Inc.; Novartis AG; and Merck & Co.
Table of Contents
Chapter 1 Methodology And Scope
1.1 Market Segmentation
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr's Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Data Visualization
1.6 Validation & Publishing
1.7 Geographic Scope & Assumptions
1.8 Region-Wise Market Calculation
1.8.1 Region-Wise Market: Base Estimates
1.9 Market Cagr Calculation
1.9.1 Region Based Segment Share Calculation
Chapter 2 Executive Summary
2.1 Ipf Treatment Market Outlook
2.2 Ipf Treatment Market: - Segment Outlook
2.3 Ipf Treatment Market: -Competitive Insights
2.4 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration And Growth Prospect Mapping
Chapter 4 Market Dynamics
4.1 Market Driver Analysis
4.1.1 Growing Geriatric Population Base
4.1.2 Growing Prevalence Of Ipf
4.1.3 Introduction Of Noverl Drugs
4.1.4 Surge In Cigarette Smoking Population
4.2 Market Restraint Analysis
4.2.1 Unavailability Of The Proper Treatment Options
Chapter 5 Ipf Treatment Market Analysis Tools
5.1 Industry Analysis - Porter's
5.1.1 Supplier Power: Low Due To Less Number Of Manufacturers
5.1.2 Buyer Power: Moderate Due To Presence Of Players Entering Into Long-Term Contract
5.1.3 Substitution Threat: Low Due To No/ Less External Substitutes
5.1.4 Threat From New Entrant: Moderate Due To Brand Recognition Of The Existing Players
5.1.5 Competitive Rivalry: Moderate Due To Increasing Mergers & Acquisitions By Major Players
5.2 Pestel Analysis
5.2.1 Political Landscape
5.2.2 Environmental Landscape
5.2.3 Social Landscape
5.2.4 Technology Landscape
5.2.5 Legal Landscape
5.3 Major Deals & Strategic Alliances Analysis
5.3.1 Joint Ventures
5.3.2 Mergers & Acquisitions
5.3.3 Licensing & Partnership
5.3.4 Technology Collaborations
5.3.5 Strategic Divestments
Chapter 6 Ipf Treatment Market - Competitive Analysis
6.1 Recent Developments & Impact Analysis, By Key Market Participants
6.2 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
6.3 Public Companies
6.3.1 Company Market Position Analysis (Revenue, Geographic Presence, Product Portfolio, Key Serviceable Industries, Key Alliances)
6.3.2 Company Market Share/Ranking, By Region
6.3.3 Competitive Dashboard Analysis
6.3.4 Market Differentiators
6.3.5 Synergy Analysis: Major Deals & Strategic Alliances
6.4 Private Companies
6.4.1 List Of Key Emerging Companies
6.4.2 Regional Network Map
6.4.3 Company Market Position Analysis (Geographic Presence, Product Portfolio, Key Alliance, Industry Experience)
Chapter 7 Drug Class Business Analysis
7.1. Definitions & Scope
7.2. Drug Class Market Share Analysis, 2018 & 2026
7.3. Ipf Treatment Market, By Drug Class, 2014 To 2026
7.4. Market Size & Forecasts And Trend Analyses, 2014 To 2026 For The Following,
7.5 Mapk Inhibitors
7.5.1 Mapk Inhibitors Market, 2014 - 2026 (Usd Million)
7.6 Tyrosine Kinase Inhibitors
7.6.1 Tyrosine Kinase Inhibitors Market, 2014 - 2026 (Usd Million)
7.7 Autotaxin Inhibitors
7.7.1 Autotaxin Inhibitors Market, 2014 - 2026 (Usd Million)
Chapter 8 Ipf Treatment Market: Regional Estimates & Trend Analysis
8.1. Definitions & Scope
8.2. Region Market Share Analysis, 2018 & 2026
8.3. Ipf Treatment Market, By Region, 2014 To 2026
8.4. Market Size & Forecasts And Trend Analyses, 2014 To 2026 For The Following,
8.5 North America.
8.5.1 North America Market Estimates And Forecast, 2014 - 2026
8.5.2 U.S.
8.5.2.1 U.S. Market Estimates And Forecast, 2014 - 2026
8.5.3 Canada
8.5.3.1 Canada Market Estimates And Forecast, 2014 - 2026
8.6 Europe
8.6.1 Europe Market Estimates And Forecast, 2014 - 2026
8.6.2 Germany
8.6.2.1 Germany Market Estimates And Forecast, 2014 - 2026
8.6.3 U.K.
8.6.3.1 U.K. Market Estimates And Forecast, 2014 - 2026
8.6.4 Spain
8.6.4.1 Spain Market Estimates And Forecast, 2014 - 2026
8.6.5 France
8.6.5.1 France Market Estimates And Forecast, 2014 - 2026
8.6.6 Italy
8.6.6.1 Italy Market Estimates And Forecast, 2014 - 2026
8.7 Asia-Pacific
8.7.1 Asia-Pacific Market Estimates And Forecast, 2014 - 2026
8.7.2 Japan
8.7.2.1 Japan Market Estimates And Forecast, 2014 - 2026
8.7.3 China
8.7.3.1 China Market Estimates And Forecast, 2014 - 2026
8.8 Latin America
8.8.1 Latin America Market Estimates And Forecast, 2014 - 2026
8.8.2 Brazil
8.8.2.1 Brazil Market Estimates And Forecast, 2014 - 2026
8.8.3 Argentina
8.8.3.1 Argentina Market Estimates And Forecast, 2014 - 2026
8.9 Middle East And Africa
8.8.1 Middle-East And Africa Market Estimates And Forecast, 2014 - 2026
8.8.2 South Africa
8.8.2.1 South Africa Market Estimates And Forecast, 2014 - 2026
8.10.Swot Analysis, By Factor (Political & Legal, Economic And Technological)
8.10.1. North America
8.10.2. Europe
8.10.3. Asia Pacific
8.10.4. Latin America
8.10.5. Middle East & Africa
Chapter 9 Competitive Landscape
9.1 Company Profiles
9.1.1 F. HOFFMAN LA ROCHE,
9.1.1.1 Company overview
9.1.1.2 Financial performance
9.1.1.3 Product benchmarking
9.1.1.4 Strategic initiatives
9.1.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Product benchmarking
9.1.2.4 Strategic initiatives
9.1.3 BRISTOL-MYERS SQUIBB COMPANY
9.1.3.1 Company overview
9.1.3.2 Financial performance
9.1.3.3 Product benchmarking
9.1.3.4 Strategic initiatives
9.1.4 MEDICINOVA, INC,
9.1.4.1 Company overview
9.1.4.2 Financial performance
9.1.4.3 Product benchmarking
9.1.4.4 Strategic initiatives
9.1.5 MERCK & CO., INC.
9.1.5.1 Company overview
9.1.5.2 Financial performance
9.1.5.3 Product benchmarking
9.1.5.4 Strategic initiatives
9.1.6 PROMETIC LIFE SCIENCES INC.
9.1.6.1 Company overview
9.1.6.2 Financial overview
9.1.6.3 Product benchmarking
9.1.6.4 Strategic initiatives
9.1.7 GALAPAGOS
9.1.7.1 Company overview
9.1.7.2 Financial overview
9.1.7.3 Product benchmarking
9.1.7.4 Strategic initiatives
9.1.8 NOVARTIS AG
9.1.8.1 Company overview
9.1.8.2 Financial overview
9.1.8.3 Product benchmarking
9.1.8.4 Strategic initiatives
9.1.9 FIBROGEN, INC.
9.1.9.1 Company overview
9.1.9.2 Financial overview
9.1.9.3 Product benchmarking
9.1.9.4 Strategic initiatives
List of Tables TABLE 1 List of abbreviation TABLE 2 North America IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 3 U.S. IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 4 Canada IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 5 Europe IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 6 Germany IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 7 U.K. IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 8 France IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 9 Italy IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 10 Spain IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 11 Asia Pacific IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 12 Japan IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 13 China IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 14 Latin America IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 15 Brazil IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 16 Argentina IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 17 MEA IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million) TABLE 18 South Africa IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
List of Figures FIG. 1 IPF treatment Market Segmentation FIG. 2 Information Procurement FIG. 3 QFD modelling for market share assessment FIG. 4 IPF treatment Market, 2018 FIG. 5 Penetration and growth prospect mapping FIG. 6 IPF treatment Market Driver Impact FIG. 7 IPF treatment Market Restraint Impact FIG. 8 SWOT Analysis, By Factor (Political & Legal, Economic and Technological) FIG. 9 Porter's Five Forces Analysis FIG. 10 IPF treatment market: Drug class outlook and key takeaways Fig. 11 IPF treatment market: Regional movement analysis FIG. 12 North America FIG. 13 North America market estimates and forecast, 2014 - 2026 FIG. 14 U.S. market estimates and forecast, 2014 - 2026 FIG. 15 Canada market estimates and forecast, 2014 - 2026 FIG. 16 Europe FIG. 17 Europe market estimates and forecast, 2014 - 2026 FIG. 18 Germany market estimates and forecast, 2014 - 2026 FIG. 19 U.K. market estimates and forecast, 2014 - 2026 FIG. 20 Spain market estimates and forecast, 2014 - 2026 FIG. 21 France market estimates and forecast, 2014 - 2026 FIG. 22 Italy market estimates and forecast, 2014 - 2026 FIG. 23 Asia Pacific FIG. 24 Asia-Pacific market estimates and forecast, 2014 - 2026 FIG. 25 Japan market estimates and forecast, 2014 - 2026 FIG. 26 China. market estimates and forecast, 2014 - 2026 FIG. 27 Latin America FIG. 28 Latin America market estimates and forecast, 2014 - 2026 FIG. 29 Brazil market estimates and forecast, 2014 - 2026 FIG. 30 Argentina market estimates and forecast, 2014 - 2026 FIG. 31 Middle East & Africa FIG. 32 MEA market estimates and forecast, 2014 - 2026 FIG. 33 South Africa market estimates and forecast, 2014 - 2026 FIG. 34 Strategic framework
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
